Web Date: March 21, 2016
Merck, Harvard sign hefty drug pact
In the largest license fee ever for a technology developed at Harvard University, Merck & Co. will pay $20 million up front for preclinical compounds for leukemia developed in the labs of chemist Matthew Shair.
Merck gains small molecules that block enzymes that control the transcription of gene expression that goes awry in acute myeloid leukemia (AML). The compounds are the culmination of several years of research in Shair’s lab, which works at the intersection . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society